Filing Flows › Vertex Pharmaceuticals (VRTX) › Total CF product revenues, net revenue
Vertex Pharmaceuticals (VRTX) Total CF product revenues, net revenue by quarter
Vertex Pharmaceuticals' Total CF product revenues, net revenue was $3.3B in Q3 2026 (third quarter 2026), +2% from Q2 2026. Over the last 3 quarters it ranged from $2.9B (Q1 2026) to $3.3B (Q3 2026).
| Quarter | Total CF product revenues, net revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.3B | +2% | — |
| Q2 2026 | $3.2B | +10% | — |
| Q1 2026 | $2.9B | — | — |
Q3 2026 at a glance
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vertex Pharmaceuticals' Total CF product revenues, net revenue?
Vertex Pharmaceuticals' Total CF product revenues, net revenue was $3.3B in Q3 2026 (third quarter 2026), +2% from Q2 2026.
How has Vertex Pharmaceuticals' Total CF product revenues, net revenue changed?
Over the last 3 quarters it ranged from $2.9B (Q1 2026) to $3.3B (Q3 2026).
Q3 2026 results → · How Vertex Pharmaceuticals makes money →